Article Details

Degrader battle sees Sanofi edged out for now

Retrieved on: 2021-10-21 23:39:06

Tags for this article:

Click the tags to see associated articles and topics

Degrader battle sees Sanofi edged out for now. View article details on hiswai:

Excerpt

Meanwhile, Roche's giredestrant has earlier shown activity in ESR1 mutants, but its Acelera study focuses on all-comers PFS. Acelera is not due to ...

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up